Johnson & Johnson is moving its coronavirus vaccine into human trials by July, 2 months ahead of schedule

• The world's largest healthcare company plans to start testing its coronavirus vaccine candidate in humans in July.
• Johnson & Johnson $4 it will move up the timeline by about two months to start clinical trials. Previously, the pharma giant was aiming to enter the clinic in September.
• The study will start in the second half of July and enroll 1,045 healthy volunteers in the US and Belgium.
• If the vaccine works, J&J has already pledged to distribute it at a nonprofit rate to help end the pandemic.

Johnson & Johnson $4 it plans to start human testing of its coronavirus vaccine candidate in July.

Previously, J&J had said the goal was to enter human trials $4. J&J is the world's largest healthcare company with a $4e of $390 billion. The company has previously pledged to distribute its vaccine on a not-for-profit basis for emergency pandemic use.

Paul Stoffels, the company's chief scientific officer, said in a news release Wednesday that the accelerated pace stemmed from "the strength" of preclinical data and conversations with regulators.

Read more: $4

The study will start in the second half of July and enroll 1,045 healthy volunteers in the US and Belgium. The initial study will have a placebo arm to compare results against. Researchers will look to see how safe and tolerable the vaccine is when injected in humans, and if it causes an immune response.

It won't be the only trial for J&J's vaccine. The company said it is talking with the US National Institutes of Health to start a larger, late-stage study "ahead of its original schedule." J&J executives have previously said they expect the vaccine to be ready by $4

J&J's program is one of more than 125 ongoing vaccine research programs. $4, and more than 25 are expected to enter the clinic by year's end.

• Read more:
• $4
• $4
• $4
• $4